Predictive Oncology Inc. (POAI)
Predictive Oncology Statistics
Share Statistics
Predictive Oncology has 8.93M shares outstanding. The number of shares has increased by 75.76% in one year.
| Shares Outstanding | 8.93M |
| Shares Change (YoY) | 75.76% |
| Shares Change (QoQ) | 8.14% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 8.8M |
| Failed to Deliver (FTD) Shares | 16.42K |
| FTD / Avg. Volume | 0.45% |
Short Selling Information
The latest short interest is 1.05M, so 14.63% of the outstanding shares have been sold short.
| Short Interest | 1.05M |
| Short % of Shares Out | 14.63% |
| Short % of Float | 14.86% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.35 and the forward PE ratio is 11.69. Predictive Oncology's PEG ratio is 0.01.
| PE Ratio | -0.35 |
| Forward PE | 11.69 |
| PS Ratio | 2.75 |
| Forward PS | 0.3 |
| PB Ratio | -22.07 |
| P/FCF Ratio | -0.41 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Predictive Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.62, with a Debt / Equity ratio of -10.52.
| Current Ratio | 0.62 |
| Quick Ratio | 0.51 |
| Debt / Equity | -10.52 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $70.6K |
| Profits Per Employee | $-550.63K |
| Employee Count | 23 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 2.14 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -19.66% in the last 52 weeks. The beta is 1.11, so Predictive Oncology's price volatility has been higher than the market average.
| Beta | 1.11 |
| 52-Week Price Change | -19.66% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 35.81 |
| Average Volume (20 Days) | 3.65M |
Income Statement
In the last 12 months, Predictive Oncology had revenue of 1.62M and earned -12.66M in profits. Earnings per share was -2.32.
| Revenue | 1.62M |
| Gross Profit | 797.68K |
| Operating Income | -10.94M |
| Net Income | -12.66M |
| EBITDA | -10.86M |
| EBIT | -10.94M |
| Earnings Per Share (EPS) | -2.32 |
Balance Sheet
The company has 734.67K in cash and 2.13M in debt, giving a net cash position of -1.4M.
| Cash & Cash Equivalents | 734.67K |
| Total Debt | 2.13M |
| Net Cash | -1.4M |
| Retained Earnings | -180.43M |
| Total Assets | 4.97M |
| Working Capital | -1.37M |
Cash Flow
In the last 12 months, operating cash flow was -10.97M and capital expenditures -9.51K, giving a free cash flow of -10.98M.
| Operating Cash Flow | -10.97M |
| Capital Expenditures | -9.51K |
| Free Cash Flow | -10.98M |
| FCF Per Share | -2.01 |
Margins
Gross margin is 49.12%, with operating and profit margins of -673.69% and -779.91%.
| Gross Margin | 49.12% |
| Operating Margin | -673.69% |
| Pretax Margin | -668.81% |
| Profit Margin | -779.91% |
| EBITDA Margin | -668.81% |
| EBIT Margin | -673.69% |
| FCF Margin | -676.44% |
Dividends & Yields
POAI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for POAI.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Apr 24, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 24, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -57.67 |
| Piotroski F-Score | 5 |